Joe nabhan

Company: K2B Therapeutics Inc.

Job title: cso

Bio:

Joe joined K2B Therapeutics as Chief Scientific Officer. Before K2B, Joe was CSO at Vesigen Therapeutics where he led innovations in non-viral genome editor delivery, a disruptive approach to genetic medicine. Before that, he spearheaded RNA biology initiatives at Astellas, launching multiple early-stage discovery programs and strategic partnerships. At Pfizer’s Rare Disease Research Unit, he drove projects from inception to lead development, managing collaborations that bridged academia and industry.

Seminars:

Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design 1:40 pm

Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins  Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload typesRead more

day: Conference Day Two